BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma

Clinical Endocrinology

Volumn 68, Issue 4, 2008, Pages 618-634

  Costa, Angela M ^a   Herrero, Agustín ^b   Fresno, Manuel F ^b   Heymann, Jonas ^c   Alvarez, José Antonio ^d   Cameselle Teijeiro, Jose ^e   García Rostán, Ginesa ^a,f  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDAD DE OVIEDO   (Spain)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SESPA   (Spain)

^e Instituto de Salud Carlos III   (Spain)

^f NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; BRAF GENE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; EXON; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEGREGATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MUTANT; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OUTCOME ASSESSMENT; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION; WILD TYPE;

CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 40749104889     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03077.x     Document Type: Article

References (58)

1. Kondo, T., Ezzat, S. Asa, S.L. (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer, 6, 292 306.
2. Bartolazzi, A., Gasbarri, A., Papotti, M., Bussolati, G., Lucante. T., Khan, A., Inohara, H., Marandino, F., Orlandi, F., Nardi, F., Vecchione, A., Tecce, R., Larsson, O. The Thyroid Cancer Study Group (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. The Lancet, 357, 1644 1650.
3. Mazzaferri, E.L. Jhiang, S.M. (1994) Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine, 97, 418 428.
4. Xing, M. (2005) BRAF mutation in thyroid cancer. Endocrine-related Cancer, 12, 245 262.
5. Ciampi, R. Nikiforov, Y.E. (2005) Alterations of the BRAF gene in thyroid tumors. Endocrine Pathology, 16, 163 171.
6. Sapio, M.R., Posca, D., Troncone, G., Pettinato, G., Palombini, L., Rossi, G., Fenzi, G. Vitale, M. (2006) Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). European Journal of Endocrinology, 154, 341 348.
7. Oler, G., Ebina, K.N., Michaluart, P., Kimura, E.T. Cerutti, J. (2005) Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clinical Endocrinology, 62, 509 511.
8. Vasko, V., Hu, S., Wu, G., Xing, J.C., Larin, A., Savchenko, V., Trink, B. Xing, M. (2005) High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. Journal of Clinical Endocrinology and Metabolism, 90, 5265 5269.
9. Vasko, V., Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V., Miyakawa, M., Isozaki, O., Murakami, H., Tsushima, T., Burman, K.D., De Micco, C. Ringel, M.D. (2004) Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. Journal of Medical Genetics, 41, 161 170.
10. Adeniran, A.J., Zhu, Z., Gandhi, M., Steward, D.L., Fidler, J.P., Giordano, T.J., Biddinger, P.W. Nikiforov, Y.E. (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristic of thyroid papillary carcinomas. American Journal of Surgical Pathology, 30, 216 222.
11. Kimura, E.T., Nikiforova, M.N., Zhu, Z., Knauf, J.A., Nikiforov, Y.E. Fagin, J.A. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research, 63, 1454 1457.
12. Garcia-Rostan, G., Costa, A.M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M.J.A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J. Santoro, M. (2005) Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Research, 65, 10199 10207.
13. Rosai, J., Carcangiu, M.L. DeLellis, R. (1992) Tumors of the thyroid gland. In : Atlas of Tumor Pathology (Series 3, fascicle 5). Armed Forces Institute of Pathology, Washington, DC.
14. Vini, L. Harmer, C. (2002) Management of thyroid cancer. Lancet Oncology, 3, 407 414.
15. Garcia-Rostan, G., Tallini, G., Herrero, A., D'Aquila, T.G., Carcangiu, M.L. Rimm, D.L. (1999) Frequent mutation and nuclear localization of β-catenin in anaplastic thyroid carcinoma. Cancer Research, 59, 1811 1815.
16. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W.C., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R. Futreal, P.A. (2002) Mutations of the BRAF gene in human cancer. Nature, 117, 949 953.
17. Garcia-Rostan, G., Zhao, H., Camp, R.L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M.L., Costa, J. Tallini, G. (2003) Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology, 21, 3226 3235.
18. Hay, I.D., Bergstralh, E.J., Goellner, J.R., Ebersold, J.R. Grant, C.S. (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1799 patients surgically treated at one institution during 1940 through 1989. Surgery, 114, 1050 1057.
19. Rouxel, A., Hejblum, G., Bernier, M.O., Boëlle, P.Y., Menegaux, F., Mansour, G., Hoang, C., Aurengo, A. Leenhardt, L. (2004) Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism, 89, 5362 5368.
20. Hoie, J., Stenwig, A.E., Kullmann, G. Lindegaard, M. (1988) Distant metastases in papillary thyroid cancer: a review of 91 patients. Cancer, 61, 1 6.
21. V600E mutations at the single-cell level in the same human melanoma. Oncogene, 25, 3357 3364.
22. Trovisco, V., Viera de Castro, I., Soares, P., Máximo, V., Silva, P., Magalhães, J., Abrosimov, A., Guiu, X.M. Sobrinho-Simões, M. (2004) BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology, 202, 247 251.
23. Carta, C., Moretti, S., Passeri, L., Barbi, F., Avenia, N., Cavaliere, A., Monacelli, M., Macchiarulo, A., Santeusanio, F., Tartaglia, M. Puxeddu, E. (2006) Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of Ras mutations and allowed the detection of a new mutation of BRAF oncoprotein BRAF (V599Ins). Clinical Endocrinology, 64, 105 109.
24. Lee, J.H., Lee, E.S., Kim, Y.S., Won, N.H. Chae, Y.S. (2006) BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology, 38, 201 204.
25. Nikiforova, M.N., Kimura, E.T., Gandhi, M., Biddinger, P.W., Knauf, J.A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., Santoro, M., Fagin, J.A. Nikiforov, Y.E. (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism, 88, 5399 5404.
26. V599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism, 89, 2414 2420.
27. V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clinical Endocrinology, 63, 461 466.
28. Trovisco, V., Soares, P., Preto, A., Vieira de Castro, I., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A.M., Magalhães, J., Abrosimov, A., Cameselle-Teijeiro, J. Sobrinho- Simões, M. (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients age but not with tumour aggressiveness. Virchows Archive, 446, 589 595.
29. Xing, M., Westra, W.H., Tufano, R.P., Cohen, Y., Rosenbaum, E., Rhoden, K.J., Carson, K.A., Vasko, V., Larin, A., Tallini, G., Tolaney, S., Holt, E.H., Hui, P., Umbricht, C.B., Basaria, S., Ewertz, M., Tufaro, A.P., Califano, J.A., Ringel, M.D., Zeiger, M.A., Sidransky, D. Ladenson, P.W. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 90, 6373 6379.
30. Fugazzola, L., Puxeddu, E., Avenia, N., Romei, C., Cirello, V., Cavaliere, A., Faviana, P., Mannavola, D., Moretti, S., Rossi, S., Sculli, M., Bottici, V., Beck-Peccoz, P., Pacini, F., Pinchera, A., Santeusanio, F. Elisei, R. (2006) Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-related Cancer, 13, 455 464.
31. Wada, N., Duh, Q.Y., Sugino, K., Iwasaki, H., Kameyama, K., Mimura, T., Ito, K., Takami, H. Takanashi, Y. (2003) Lymph node metastases from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Annals of Surgery, 237, 399 407.
32. Frazell, E.L. Foote, F.V. (1955) Papillary thyroid carcinoma. Pathological findings in cases with and without clinical evidence of cervical node involvement. Cancer, 8, 1165 1166.
33. Antonelli, A., Miccoli, P., Fallahi, P., Ferrari, S., Grosso, M., Boni, G. Berti, P. (2003) Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid, 13, 479 484.
34. Lerch, H., Schober, O., Kuwert, T. Saur, H.B. (1997) Survival of differentiated thyroid carcinoma studied in 500 patients. Journal of Clinical Oncology, 15, 2067 2075.
35. Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T.I., Ohtsuru, A., Saenko, V.A., Kanematsu, T. Yamashita, S. (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism, 88, 4393 4397.
36. Sedliarou, I., Saenko, V., Lantsov, D., Rogounovitch, T., Namba, H., Abrosimov, A., Lushnikov, E., Kumagai, A., Nakashima, M., Meirmanov, S., Mine, M., Hayashi, T. Yamashita, S. (2004) The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. International Journal of Oncology, 25, 1729 1735.
37. Zuo, H., Nakamura, Y., Yasuoka, H., Zhang, P., Nakamura, M., Mori, I., Miyauchi, A. Kakudo, A. (2007) Lack of MAPK activation in papillary thyroid carcinoma with BRAF V600E mutation. Pathology International, 57, 12 20.
38. Kim, T.Y., Kim, W.B., Song, J.Y., Rhee, Y.S., Gong, G., Cho, Y.M., Kim, S.Y., Kim, S.C., Hong, S.J. Shong, Y.K. (2005) The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary microcarcinoma. Clinical Endocrinology, 63, 588 593.
39. V600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Research, 65, 2465 2473.
40. Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K. Takenoshita, S. (2003) BRAF mutations in papillary carcinomas of the thyroid. Oncogene, 22, 6455 6457.
41. Soares, P., Trovisco, V., Rocha, A.S., Lima, J., Castro, P., Preto, A., Maximo, V., Botelho, T., Seruca, R. Sobrinho-Simões, M. (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 22, 4578 4580.
42. Garcia-Rostan, G., Camp, R.L., Herrero, A., Carcangiu, M.L., Rimm, D.L. Tallini, G. (2001) β-catenin dysregulation in thyroid neoplasms. Down-regulation, aberrant nuclear expression and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. American Journal of Pathology, 158, 987 996.
43. Eng, C., Thomas, G.A., Neuberg, D.S., Mulligan, L.M., Healey, C.S., Houghton, C., Frilling, A., Raue, F., Williams, E.D. Ponder, B.A. (1998) Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 83, 4310 4313.
44. Puxeddu, E., Zhao, G., Stringer, J.R., Medvedovic, M., Moretti, S. Fagin, J.A. (2005) Characterization of novel non-clonal intrachromosomal rearrangement between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mutation Research, 570, 17 32.
45. Bounacer, A., Wicker, R., Caillou, B., Cailleux, A.F., Sarasin, A., Schlumberger, M. Suarez, H.G. (1997) High prevalence of activating ret proto-oncogene rearrangements in thyroid tumors from patients who had received external radiation. Oncogene, 15, 1263 1273.
46. Sugg, S.L., Ezzat, S., Zheng, L., Freeman, J.L., Rosen, I.B. Asa, S.L. (1999) Oncogene profile of papillary thyroid carcinoma. Surgery (St. Louis), 125, 46 52.
47. T1796A mutations in childhood thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism, 89, 4280 4284.
48. Xu, X., Quiros, R.M., Gattuso, P., Ain, K.B. Prinz, R.A. (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research, 63, 4561 4567.
49. Pollock, P.M., Harper, U.L., Hansen, K.S., Yudt, L.M., Stark, M., Robbins, C.M., Moses, T.Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N.K., Trent, J.M. Meltzer, P.S. (2003) High frequency of BRAF mutations in nevi. Nature Genetics, 33, 19 20.
50. Kumar, R., Angelini, S. Hemminki, K. (2003) Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene, 22, 9217 9224.
51. Lee, S.H., Lee, J.W., Soung, Y.H., Kim, H.S., Park, W.S., Kim, S.Y., Lee, J.H., Park, J.Y., Cho, Y.G., Kim, C.J., Nam, S.W., Kim, S.H., Lee, J.Y. Yoo, N.J. (2003) BRAF and KRAS mutations in stomach cancer. Oncogene, 22, 6942 6945.
52. Oliveira, C., Velho, S., Moutinho, C., Ferreira, A., Preto, A., Domingo, E., Capelinha, A.F., Duval, A., Hamelin, R., Machado, J., Schwartz, S., Carneiro, F. Seruca, R. (2007) KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene, 26, 158 163.
53. Zhu, J., Woods, D., McMahon, M. Bishop, J.M. (1998) Senescence of human fibroblast induced by oncogenic Raf. Genes and Development, 12, 2997 3007.
54. Lin, A.W., Barradas, M., Stone, J.C., van Aelst, L., Serrano, M. Lowe, S.W. (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signalling. Genes and Development, 12, 3008 3019.
55. E600-associated senescence-like cell cycle arrest of human naevi. Nature, 436, 720 724.
56. Patton, E.E., Widlund, H.R., Kutok, J.L., Kopani, K.R., Amatruda, J.F., Murphey, R.D., Berghmans, S., Mayhall, E.A., Traver, D., Fletcher, C.D., Aster, J.C., Granter, S.R., Look, A.T., Lee, C., Fisher, D.E. Zon, L.I. (2005) BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Current Biology, 15, 249 254.
57. Kim, J.S., Lee, C., Foxworth, A. Waldman, T. (2004) B-Raf is dispensable for K-ras-mediated oncogenesis in human cancer cells. Cancer Research, 64, 1932 1937.
58. V599EB-RAF is an oncogene in melanocytes. Cancer Research, 64, 2338 2342.